| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1074221584 |
| P356 | DOI | 10.1007/S10096-017-2900-4 |
| P698 | PubMed publication ID | 28127641 |
| P50 | author | Sébastien Chanoine | Q63374419 |
| Charlotte Dentan | Q96197692 | ||
| P2093 | author name string | M Roustit | |
| E Forestier | |||
| S Boisset | |||
| P Pavese | |||
| O Epaulard | |||
| P2860 | cites work | European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid | Q26823518 |
| Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 | Q29615429 | ||
| Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data | Q31011382 | ||
| Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections | Q33347869 | ||
| Successful treatment of chronic bone and joint infections with oral linezolid. | Q33363767 | ||
| Intrapulmonary pharmacokinetics of linezolid | Q34106719 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| Clinical management of Staphylococcus aureus bacteremia: a review | Q34441035 | ||
| Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus | Q34452009 | ||
| Linezolid for the treatment of adults with bone and joint infections | Q34597999 | ||
| The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections | Q34618696 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials | Q34923394 | ||
| Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients | Q34991274 | ||
| Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 | ||
| Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin | Q35959546 | ||
| Clinical audit of linezolid use in a large teaching hospital | Q36157587 | ||
| Prospective assessment of fluoroquinolone use in a teaching hospital. | Q36637993 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Factors affecting the uptake of new medicines in secondary care - a literature review. | Q37211304 | ||
| Management of methicillin-resistant Staphylococcus aureus infections | Q37416330 | ||
| Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates | Q37809666 | ||
| Multiresistant bacteria and current therapy - the economical side of the story | Q37821606 | ||
| MRSA: the first half century | Q37947249 | ||
| The emerging problem of linezolid-resistant Staphylococcus | Q38040775 | ||
| Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter | Q38061039 | ||
| The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. | Q38061547 | ||
| Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis | Q38255278 | ||
| Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients | Q39487652 | ||
| Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients | Q40594509 | ||
| An assessment of linezolid utilization in selected canadian provinces | Q40672033 | ||
| Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 | ||
| Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain | Q41644243 | ||
| Controlling antibiotic resistance by quelling the epidemic of overuse and misuse of antibiotics | Q43091637 | ||
| Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey | Q43416792 | ||
| Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial | Q43546278 | ||
| Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
| Staphylococcus aureus meningitis with intermediate sensitivity to glycopeptides. Therapeutic indications | Q44334169 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? | Q45394930 | ||
| The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia | Q45749888 | ||
| Improving linezolid use decreases the incidence of resistance among Gram-positive microorganisms | Q46207086 | ||
| Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies | Q46728767 | ||
| Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. | Q46766488 | ||
| Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). | Q46940422 | ||
| Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. | Q46983297 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study | Q64028001 | ||
| Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus | Q80282093 | ||
| Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus | Q80581252 | ||
| Linezolid audit: similarities and contrasts with published experience | Q82890155 | ||
| Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009 | Q83215855 | ||
| P433 | issue | 7 | |
| P921 | main subject | linezolid | Q411377 |
| P304 | page(s) | 1133-1141 | |
| P577 | publication date | 2017-01-26 | |
| P1433 | published in | European Journal of Clinical Microbiology & Infectious Diseases | Q15754378 |
| P1476 | title | Assessment of linezolid prescriptions in three French hospitals | |
| P478 | volume | 36 |
Search more.